Compounds > zd 8321
Page last updated: 2024-11-12

zd 8321

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ZD 8321: inhibits human leukocyte elastase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9910174
CHEMBL ID79463
SCHEMBL ID5801511
MeSH IDM0282320

Synonyms (22)

Synonym
CHEMBL79463 ,
zd-8321
{(s)-2-methyl-1-[(s)-2-((s)-3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester
{2-methyl-1-[2-(3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-pyrrolidine-1-carbonyl]-propyl}-carbamic acid methyl ester(zd8321)
bdbm50061024
(2-methyl-1-{(s)-oxo-[(s)-2-((s)-3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-pyrrolidin-1-yl]-methyl}-propyl)-carbamic acid methyl ester
SCHEMBL5801511
(s)-1-[(s)-2-(methoxycarbonylamino)-3-methylbutyryl]-n-[(s)-2-methyl-1-(2,2,2-trifluoroacetyl)propyl]-pyrrolidine-2-carboxamide
unii-t7fia2s66d
l-prolinamide, n-(methoxycarbonyl)-l-valyl-n-((1s)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl)-
t7fia2s66d ,
n-(methoxycarbonyl)-l-valyl-n-((1s)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl)-l-prolinamide
182073-77-4
1-(2-methoxycarbonyl-3-methylbutyryl)-n-(2-methyl-1-(trifluoroacetyl)propyl)pyrrolidine-2-carboxamide
zd 8321
CS-7453
zd8321
HY-U00256
methyl ((s)-3-methyl-1-oxo-1-((s)-2-(((s)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl)pyrrolidin-1-yl)butan-2-yl)carbamate
methyl n-[(2s)-3-methyl-1-oxo-1-[(2s)-2-[[(3s)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamate
n''-[n-methoxycarbonyl-l-valyl]-n-[(s)-3,3,3-trifluor-1-isopropyl-2-oxopropyl]-l-prolinamide
AKOS040742842

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Two of these compounds, 1k and 1l, have high levels of oral bioavailability in several species."( Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
Bernstein, PR; Bohnert, CM; Brown, FJ; Bryant, C; Damewood, JR; Earley, R; Edwards, PD; Feeney, SW; Gomes, B; Hulsizer, JM; Kosmider, BJ; Krell, RD; Moore, G; Salcedo, TW; Shaw, A; Silberstein, DS; Steelman, GB; Stein, M; Strimpler, A; Thomas, RM; Vacek, EP; Veale, CA; Williams, JC; Wolanin, DJ; Woolson, S, 1997)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trypsin-1Homo sapiens (human)Ki66.60000.00001.76768.9000AID215410
Neutrophil elastaseHomo sapiens (human)Ki0.01300.00201.28669.5499AID66679; AID66981
Chymotrypsin-like elastase family member 2ASus scrofa (pig)Ki0.01300.01300.01300.0130AID155063
Chymotrypsin-CHomo sapiens (human)Ki0.14900.00100.92403.7000AID52607
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
proteolysisChymotrypsin-CHomo sapiens (human)
intracellular calcium ion homeostasisChymotrypsin-CHomo sapiens (human)
proteolysisChymotrypsin-CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
protein bindingChymotrypsin-CHomo sapiens (human)
peptidase activityChymotrypsin-CHomo sapiens (human)
serine-type endopeptidase activityChymotrypsin-CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID14572Oral integrated area under the concentration vs time curve, for compound in rat plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID155063Binding affinity for porcine Pancreatic elastase1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID20764Time of maximum concentration of compound in rat plasma.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID95036Binding affinity for human urine kallikrein; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID14081Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID25939Half-life of compound in plasma of hamster1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID84841Effective dose in the Acute Hemarrhagic Assay model after oral administration1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID52607Binding affinity for human pancreatic Chymotrypsinogen1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID26950Oral bioavailability in dog2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID14571Oral integrated area under the concentration vs time curve, for compound in hamster plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID51211Binding affinity for bovine spleen cathepsin L; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID48490Binding affinity for carboxypeptidase A; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID215410Binding affinity for human pancreatic trypsin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID37798Binding affinity for rabbit lung Angiotensin I converting enzyme; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID48218Binding affinity for human leukocyte cathepsin G; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID20762Time of maximum concentration of compound in dog plasma.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID20763Time of maximum concentration of compound in hamster plasma.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID25940Half-life of compound in plasma of rat1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID31616Binding affinity for human erythrocyte Acetylcholinesterase; Not tested1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID210995Binding affinity for human plasma thrombin; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID14079Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID14560Intravenous integrated area under the concentration vs time curve, for compound in dog plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID18628Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID95040Binding affinity for human plasma kallikrein; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID223086In vitro inhibitory activity in human whole blood (HWB) elastase2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Intracellular inhibition of human neutrophil elastase by orally active pyrrolidine-trans-lactams.
AID20791oral bioavailability in Hamsters2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID14562Intravenous integrated area under the concentration vs time curve, for compound in rat plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID14080Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID14561Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID66981oral activity of the compound2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID84840Effective dose in the Acute Hemarrhagic Assay model after i.v. administration1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID14569Oral integrated area under the concentration vs time curve, for compound in dog plasma1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID26953Oral bioavailability in rat2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID229067The in vivo activity ED50 (oral)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID18630Bioavailability in rat1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID85510Percent inhibition of elastase-induced lung damage by 10 mg/kg dosed orally, 30 minutes prior to the instillation of 50 ug of elastase1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID229066The in vivo activity ED50 (iv)2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID155252Binding affinity for papaya papain; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID229675Selectivity ratio refers to the ratio K1 [porcine pancreatic elastase)/Ki(HLE)]1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID229674Selectivity ratio refers to the ratio K1 [human pancreatic chymotrypsin)/Ki(HLE)]1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID25938Half-life of compound in plasma of dog1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID125234Binding affinity for human plasma monoamine oxidase; No inhibition at 188 uM (highest concentration tested)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID18629Bioavailability in hamster1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
AID66679Binding affinity for human leukocyte elastase1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		3.110azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		3.110biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
fidexaban
Fidexaban: structure in first source		3.110
nafamostat
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic		3.110benzoic acids;
guanidines
thiazoles
[no description available]		2.01101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		3.110alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
quinapril
Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.		3.110dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
nelfinavir
Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.		3.110aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
amprenavir
[no description available]		3.110carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
inogatran
inogatran: a direct low molecular weight thrombin inhibitor		3.110
palinavir
[no description available]		3.110N-acyl-amino acid
calpeptin
[no description available]		3.110amino acid amide
moexipril
[no description available]		3.110peptide
zofenopril
zofenopril: structure given in first source; SQ 26900 refers to K salt & SQ 26991 to Ca salt. zofenopril : A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat.		3.110aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester		anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent
mci 9038
[no description available]		3.110peptide
lopinavir
[no description available]		3.110amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		3.110N-acylglycine;
pivalate ester
sepimostate mesilate
sepimostate mesilate: used in therapy of pancreatitis; structure given in first source		3.110
l 658758
L 658758: structure & chemical name given in UD		3.110
ici 200355
ICI 200355: structure given in first source		1.9910
dx 9065
[no description available]		3.110
acetylphenylalanyl-prolyl-boroarginine
Ac-(D)Phe-Pro-boroArg-OH : A C-terminal boronic acid petide that is N-acetyl-D-phenylalanyl-L-prolyl-L-arginine in which the C-termnal carboxy group has been replaced by a borono (-B(OH)2) group. A thrombin (Factor IIa) inhibitor, thereby acting as an anticoagulant.. DuP-714 : A hydrochloride resulting from the formal reaction of equimolar amounts of Ac-(D)Phe-Pro-boroArg-OH and hydrogen chloride. A thrombin (Factor IIa) inhibitor, thereby acting as an anticoagulant.		3.110acetamides;
C-terminal boronic acid peptide;
guanidines		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor
e 64
E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)		3.110dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone
benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone: inhibits cathepsins B and L		3.110carboxylic ester;
diazo compound;
L-phenylalanine derivative;
secondary carboxamide		cathepsin L (EC 3.4.22.15) inhibitor
atazanavir
atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).		3.110carbohydrazideantiviral drug;
HIV protease inhibitor
bila 2157 bs
BILA 2157 BS: renin inhibitor; RN given for (1S-(1R*(S*),2S*,3R*))-isomer; structure in first source		3.110
l 694,458
DMP 777: structure given in first source		210
melagatran
[no description available]		3.110azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		3.1101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
elastin
[no description available]		2.0110oligopeptide
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		3.110L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
candoxatrilat
candoxatrilat: USAN lists candoxatrilat (UK-73,967) with RN 123122-54-3. candoxatrilat : A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.		3.110
cgp 38560a
[no description available]		3.110
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.		3.110amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
prinomastat
prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor;. prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14.		3.110aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines		antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
rs-130830
RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor		3.110
thiorphan
[no description available]		3.110
alatriopril
alatriopril: shows promise for the treatment of various cardiovascular & salt-retention disorders		3.110
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		3.110dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril
benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.		3.110benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ramipril
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.		3.110azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		3.110dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		3.110dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		3.110pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
trandolapril
trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.		3.110dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
ro 42-5892
remikiren : An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued).		3.110cyclopropanes;
diol;
L-histidine derivative;
secondary carboxamide;
sulfone		antihypertensive agent;
EC 3.4.23.15 (renin) inhibitor;
peptidomimetic;
vasodilator agent
rupintrivir
rupintrivir: a rhinovirus 3C protease inhibitor		3.110
napsagatran
napsagatran: structure given in first source		3.110
bay 12-9566
Bay 12-9566: an angiogenesis inhibitor with matrix metalloproteinase inhibitory activity		3.110biphenyls;
organochlorine compound
fosinopril
[no description available]		3.110
ym 60828
YM 60828: YM-466 is the mesylate salt		3.110
ro 32-3555
Ro 32-3555: structure given in first source		3.110
ssr 69071
SSR 69071: structure in first source		2.0110pyridopyrimidine
ConditionIndicatedRelationship StrengthStudiesTrials
Anasarca
[description not available]		02.0110
Bleeding
[description not available]		02.0110
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0110
Hemorrhage
Bleeding or escape of blood from a vessel.		02.0110
Cancer of Colon
[description not available]		0210
Cancer of Pancreas
[description not available]		0210
Colonic Neoplasms
Tumors or cancer of the COLON.		0210
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		0210